Click Download or Read Online button to get a textbook on edta chelation therapy book now. This site is like a library, Use search box in the widget to get ebook that you want. Author by : Elmer M. Saftey and effectivenss are well documented in clinical studies, all of which to date are supportive of this therapy, and there are no studies showing lack of effectiveness.
|Published (Last):||12 November 2009|
|PDF File Size:||4.48 Mb|
|ePub File Size:||2.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
Cranton, M. Renewed research into the potential benefits of EDTA chelation therapy has sparked increasing interest from clinicians and scientists around the world.
Physicians experienced in the use of EDTA are often asked for pertinent clinical data and for guidance on how to safely administer the therapy. This text is designed to provide a compilation of the most current and pertinent information on that subject. While processing applications for research permits, the FDA has searched extensively for reports of adverse or poor results, including serious side effects, stemming from EDTA chelation therapy as it is now routinely administered.
The FDA could find no such evidence. An official request was sent from the FDA to state health and regulatory agencies across the United States asking that any information relating to untoward results, poor results, or patient complaints about EDTA chelation therapy be forwarded to the FDA. No reports of that type were received by the FDA in response to their request.
A large body of published research has been presented to the FDA showing that EDTA is safer than many other more widely accepted therapies. Increasing Criticism of Bypass Surgery Many medical authorities have become increasingly critical of bypass surgery. Thomas A. Preston, M. The operation does not cure patients, it is scandalously overused and its high cost drains resources from other areas of need. He further says, A decade of scientific study has shown that except in certain well defined situations, bypass surgery does not save lives or even prevent heart attacks.
Among patients who suffer from coronary artery disease, those who are treated without surgery enjoy the same survival rates as those who undergo open heart surgery. Yet many American physicians continue to prescribe surgery immediately upon the appearance of angina or chest pain. That study included victims of atherosclerotic heart disease of the most critical kind with unstable angina pectoris.
Half were subjected to bypass surgery and the other half were treated without surgery. The overall two-year survival rate did not differ between surgically-treated patients and those who were treated without surgery, and the incidence of myocardial infarction was not significantly different. Those results are very similar to the previously published CASS study.
Both types of prescription medicine have been shown to reduce the incidence of myocardial infarction, decrease death rate in coronary artery disease, and relieve angina without surgery. It is therefore not possible to conclude whether patients would not do equally as well or even better without surgery unless further research is done to compare bypass surgery with present-day medicines and chelation therapy. Another report in the New England Journal of Medicine in showed that coronary blood vessels increase in size as plaques occur.
When a plaque grows to approach 50 percent of the lumen of a coronary artery, the artery simultaneously enlarges to compensate. The diseased artery therefore continues to allow the same flow of blood as a healthy artery. At that point, collateral circulation will often maintain an adequate supply of blood, even when a major vessel becomes totally blocked. With 75 percent blockage from plaque, compensatory enlargement causes overall blood flow to remain equal to that in a healthy artery with only a 50 percent blockage.
Furthermore, animal experiments show that more than 50 percent blockage of a normal coronary artery is necessary to decrease heart function, even under maximum physical stress.
More than 75 percent blockage of an artery, without time to compensate, is needed to impair cardiac function at rest. Nonetheless, bypass surgery is aggressively recommended in many instances with plaque blockage of 75 percent or less, despite adequate coronary blood flow.
An editorial in that same issue of the New England Journal of Medicine stated, Those…who perform coronary arteriography have made one serious mistake. It consists of the unfortunate adoption of a grading system for stenoses expressed as a percentage of the arterial lumen that is compromised. This grading system implies a degree of accuracy that coronary angiography cannot achieve.
It is not possible to accurately predict the three-dimensional flow of blood in an artery from two-dimensional x-ray shadows. That editorial goes on to point out that 75 percent blockage of a diseased coronary vessel is therefore necessary to even begin to compromise the heart with maximum stress, and that considerably more than a 75 percent plaque blockage is necessary to reduce cardiac function without strenuous physical exertion.
Arterial spasm, best treated without surgery, can cause anginal pain and myocardial infarction, even without atherosclerotic plaque. Reversible spasm can also be triggered by irritation from contrast media and diminished oxygen transport during catheterization, which can closely mimic atherosclerotic plaque. Why then are patients so often told they must have bypass surgery on the basis of arteriograms showing a 75 percent blockage, with little consideration for overall heart function and total coronary flow?
Why is the heart not routinely evaluated with non-invasive technetium and thallium radioisotope imaging, before proceeding with surgery? Is it because isotope imaging will so often show efficient cardiac function and adequate coronary perfusion, despite the abnormal arteriograms? Is it possible that isotope studies are so seldom done because surgery might be canceled if results of noninvasive imaging did not agree with arteriography?
Arteriograms are a major marketing tool for bypass surgery and balloon or now laser angioplasty. Catheterization and arteriograms are too often used to frighten patients into accepting unnecessary, dangerous, and expensive surgery or angioplasty, when nonsurgical treatment would be equally as effective or more so, with less danger and expense.
The risk of harm or death to the patient, even from the catheterization and arteriograms, is significant. Arteriograms should be used only after all else has failed, after a decision to consider surgery or angioplasty has been made, based on severity of symptoms and lack of response to nonsurgical treatments including chelation therapy. Another reason to delay surgery whenever possible is a recent report of accelerated atherosclerosis in coronary arteries after they have been subjected to bypass.
Plaques grow faster after surgery. When a bypassed artery is only partially blocked, as is often the case, thrombosis and total occlusion of the bypassed segment, up to the point of bypass, can more easily occur, creating total dependence on a thin-walled and weaker vein graft.
When that vein graft fails, the patient is worse off than before surgery. The Congress of the United States, Office of Technology Assessment, has criticized the unproven character of bypass surgery and many other commonly performed medical procedures. Instead, the number of bypass operations has increased from , in to , in , at a time when angioplasty procedures increased from 46, to , per year.
Angioplasties often fail in less than a year, leading to repeated angioplasties or bypass surgery. Angioplasty can also damage an artery, exposing collagen to platelet aggregation and rapid clotting, making chelation therapy and other nonsurgical treatments less effective.
The Chelation Alternative Patients are rarely told about chelation therapy before bypass surgery or angioplasty, although chelation is hundreds of times safer at a small fraction of the cost. If asked, cardiologists and bypass surgeons will usually criticize chelation therapy and press for the much more profitable catheterization and bypass surgery or angioplasty.
This text presents a compilation of data to support the clinical effectiveness of EDTA chelation therapy for the treatment of atherosclerotic cardiovascular disease. Results of clinical trials are published in this volume. All support this therapy. Clinical research relating to EDTA chelation therapy came to a virtual standstill in the early s, as bypass surgery first came into vogue.
Even limited studies of chelation therapy were not resumed until the s. Perhaps that timing was mere coincidence, but the fact remains that discontinuance of chelation research might historically be the greatest wind-fall to surgeons and hospitals since the discovery of general anesthesia.
The leading investigator of chelation therapy in the early s, Dr. In contradiction to his data, Kitchell ended that report with a negative conclusion. A careful search of the scientific literature in shows no negative data which refutes the usefulness of EDTA chelation therapy.
Adverse reports have either been editorial in nature or totally anecdotal, with no supporting scientific evidence to contradict the growing body of evidence which supports the safety and clinical effectiveness of EDTA. Most criticisms of chelation therapy continue to originate from individuals with vested interests in competing therapies. The American College for Advancement in Medicine maintains an extensive library of scientific literature relating to EDTA chelation therapy, including many of the articles listed as references to chapters throughout this book.
Preston TA. Marketing an operation: Coronary artery bypass surgery. J Holistic Med ;7 1 Comparison of medical and surgical treatment for unstable angina pectoris.
N Engl J Med ; 16 Circulation ; 68 5 N Engl J Med ; 12 Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med ; 22 Paulin S. Assessing the severity of coronary lesions with angiography.
Accelerated progression of atherosclerosis in coronary vessels with minimal lesions that are bypassed. N Engl J Med ; 13 The appropriateness of performing coronary artery bypass surgery.
JAMA ; Assessing the Efficacy and Safety of Medical Technologies. The treatment of coronary artery disease with disodium EDTA, a reappraisal. Am J Cardiol ; J Holistic Med ;4 l Introduction to the Second Edition Elmer M. Much new information and research has become available since publication of the First Edition of this textbook. In this updated Second Edition, I have included data from a number of clinical trials performed since the original publication.
Other chapters have been extensively updated to reflect current practice and theory. Chapters are written by many different experts in this field. The reader will find some contradictions. This is an evolving field of science, and experts rarely agree in all areas of their expertise.
A Textbook on EDTA Chelation Therapy: Second Edition
Download eBook Chelation therapy, based on the intravenous infusion of EDTA, is a highly effective treatment for atherosclerotic cardiovasular disease. Saftey and effectivenss are well documented in clinical studies, all of which to date are supportive of this therapy, and there are no studies showing lack of effectiveness. A strong case is made for the use of this safe, efficacious, and inexpensive therapy before resorting to surgery and other risky and invasive treatments. In this newly revised and extensively updated edition of what has come to be regarded as the definitive textbook on the subject, renowned chelation expert Elmer M. Cranton, M. Linus Pauling states, "EDTA chelation therapy makes good sense to me as a chemist and medical researcher. It has a rational scientific basis, and the evidence for clinical benefit seems to be quite strong.
A textbook on EDTA chelation therapy
Search Home Dr. Lamas found extraordinary results, particularly relating to diabetic patients. The most widely accepted use of chelation therapy is for the removal of toxic minerals such as lead from the body. A more controversial indication, discovered serendipitously during treatment of patients suffering with lead toxicity, involving the use of the chelating agent disodium ethylene diaminetetraacetic acid EDTA , is in the treatment of all forms of atherosclerotic cardiovascular disease. Clarke, Sr. Seven, who was associated with the National Institutes of Health, was killed in auto accident in